TLX•globenewswire•December 21, 2025 at 09:38 PM

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

Summary

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relation to:

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on December 21, 2025 by globenewswire